» Articles » PMID: 39234650

Knowledge of Medications for Opioid Use Disorder and Associated Stigma Among Primary Care Professionals

Overview
Journal Ann Med
Publisher Informa Healthcare
Specialty General Medicine
Date 2024 Sep 5
PMID 39234650
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Medications for opioid use disorder (MOUD) are the gold standard. However, significant barriers limit their use in the primary care setting, including limited knowledge of the medications and stigmatizing attitudes. In this study, we assess knowledge levels among primary care-aligned professionals (PCPs) currently in practice, and whether knowledge of MOUD is associated with stigma and treatment attitudes.

Participants And Methods: Using rosters from the state of Ohio licensing boards, we surveyed 403 physicians, nurse practitioners, and physician associates in 2022, on the mechanism of different MOUD, as well as stigma and treatment attitudes. To assess MOUD knowledge, we employed descriptive and bivariate statistics. We fit four linear regression models, which controlled for empathy towards patients with OUD and provider demographics to assess the relationship between MOUD knowledge and four endpoints: stigma, perceived controllability of opioid use, perceived vulnerability to opioid use disorder, and support for abstinence-only treatment.

Results: 43% of participants correctly identified the mechanism of all 3 medications whereas 13% of participants did not identify the mechanism of any MOUD correctly. MOUD knowledge was higher among physicians as compared to nurse practitioners and physician associates. Lower MOUD knowledge was associated with more negative attitudes towards patients with OUD and MOUD treatment.

Conclusion: Expanding access to MOUD treatment requires a trained and willing health-care professional (HCP) workforce. Our findings highlight considerable variation in clinician knowledge of MOUD and suggest that knowledge levels are also related to negative attitudes towards patients with OUD and MOUD. Training interventions that increase knowledge, as well as focus on stigma reduction, are critical for reducing the longstanding treatment gap for opioid use disorder.

Citing Articles

Understanding MAT access in the context of unused MAT capacity in the United States: when increasing rural MAT capacity is not enough.

Mun C, Zambrano R, Tallman E, Schuler H, Bresani E, Meyers K Subst Abuse Treat Prev Policy. 2024; 19(1):47.

PMID: 39707473 PMC: 11662619. DOI: 10.1186/s13011-024-00628-4.


The Implementation Climate for Integrating Buprenorphine Prescribing into Rural Primary Care.

Fenstemaker C, Abrams E, King K, Obringer B, Brook D, Go V J Gen Intern Med. 2024; .

PMID: 39668316 DOI: 10.1007/s11606-024-09260-1.

References
1.
Waller R, Clark K, Woodruff A, Glossa J, Ostrovsky A . Guide for Future Directions for the Addiction and OUD Treatment Ecosystem. NAM Perspect. 2021; 2021. PMC: 8406500. DOI: 10.3147/202104b. View

2.
Austin E, Briggs E, Ferro L, Barry P, Heald A, Curran G . Integrating Routine Screening for Opioid Use Disorder into Primary Care Settings: Experiences from a National Cohort of Clinics. J Gen Intern Med. 2022; 38(2):332-340. PMC: 9132563. DOI: 10.1007/s11606-022-07675-2. View

3.
Chen L, Sethi S, Poland C, Frank C, Tengelitsch E, Goldstick J . Prescriptions for Buprenorphine in Michigan Following an Education Intervention. JAMA Netw Open. 2023; 6(12):e2349103. PMC: 10739087. DOI: 10.1001/jamanetworkopen.2023.49103. View

4.
Corrigan P, Penn D . Lessons from social psychology on discrediting psychiatric stigma. Am Psychol. 1999; 54(9):765-76. DOI: 10.1037//0003-066x.54.9.765. View

5.
Lundin R, Hill H . The worrying, current state of addictions training in medicine. Front Med (Lausanne). 2022; 9:1062096. PMC: 9731765. DOI: 10.3389/fmed.2022.1062096. View